The new stage in the development of a system for the treatment and rehabilitation of patients with schizophrenic spectrum disorders

Aim. Evaluation of statistical data on the prevalence of patients with schizophrenic spectrum disorders in Moscow, to substantiate a new stage of the development of out-patients system of treatment and rehabilitation of this category of patients.

Methods. There is considered trend of the accounted contingent of patients with schizophrenic spectrum disorders in Moscow for fifteen years (2004-2018).

Results. There is a decrease in the number of patients with schizophrenic spectrum disorders (from 0.53% to 0.44% of the permanent population of Moscow) under observation in the state health care system, which is explained by the processes of deinstitutionalization and a shift in emphasis towards the outpatient level of psychiatric care. From the standpoint of the biopsychosocial approach, the tendency to change the ratio of observed male and female patients (increase in the proportion of male patients and decrease in female) over the specified period is discussed. The article analyzes the draft of the new version of the international classification of mental and behavioral disorders (ICD-11) in terms of schizophrenic spectrum disorders in terms of optimizing psychiatric care for this contingent of patients.

Conclusion. The observed changes in the considered contingent of patients and the introduction of new approaches to the diagnosis and therapy of patients with schizophrenic spectrum disorders indicate the onset of a new stage in the development of out-patient treatment and rehabilitation system based on the latest achievements of psychopharmacology and the development of social support systems for patients with mental disorders.

1. Awad A.G., Voruganti L.N. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008; 26(2): 149-62. https://doi.org/10.2165/00019053-200826020-00005

2. Tiganov A.S., ed. Handbook of Psychiatry. Volume 1 [Rukovodstvo po psikhiatrii. Tom 1]. Moscow: Meditsina; 1999. (in Russian)

3. Kaplan H.I., Sadock B.J. Pocket Handbook of Clinical Psychiatry. Baltimore: Williams and Wilkins; 1990: 143-74.

4. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.E., et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organisation 10-Country Study. Psychol. Med. Monogr. Suppl. 1992; 20: 1-97. https://doi.org/10.1017/s0264180100000904

5. Snezhnevskiy A.V., ed. Schizophrenia: Clinical Features and Pathogenesis [Shizofreniya: Klinika i patogenez]. Moscow: Meditsina; 1969. (in Russian)

6. Kendler K.S., Gardner C.O. The risk for psychiatric disorders in relatives of schizophrenic and control probands: a comparison of three independent studies. Psychol. Med. 1997; 27(2): 411-9. https://doi.org/10.1017/s003329179600445x

7. World Health Organization. Schizophrenia. Available at: http://www.who.int/news-room/fact-sheets/detail/schizophrenia

8. Byrne P. Stigma of mental illness and ways of diminishing it. Adv. Psychiatr. Treat. 2000; 6(1): 65-72. https://doi.org/10.1192/apt.6.1.65

9. Yastrebov V.S. Organization of mental health care: A historical sketch. In: Tiganov A.S., ed. Handbook of Psychiatry. Volume 1 [Rukovodstvo po psikhiatrii. Tom 1]. Moscow: Meditsina; 1999. (in Russian)

10. Tsyganok L.А. Reforming of psychiatric service. Experience of the USA and Europe. Independent psychiatric journal. Nezavisimyy psikhiatricheskiy zhurnal. 2007; (3): 64-74. (in Russian)

11. World Health Organization. Comprehensive mental health action plan 2013 – 2020. Available at: http://www.who.int/mental_health/mhgap/consultation_global_mh_action_plan_2013_2020/en/index.html

12. Melik-Guseynov D.V. Psychiatric Service of the City of Moscow: From the Audit to Management Decisions. Available at: https://mosgorzdrav.ru/ru-RU/magic/default/download/5027.html (in Russian)

13. Mosstat. Official statistics. Moscow. Population. Available at: https://mosstat.gks.ru/folder/64634 (in Russian)

14. Riecher-Rössler A., Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. Suppl. 2000; (407): 58-62. https://doi.org/10.1034/j.1600-0447.2000.00011.x

15. Robins L.N., Helzer J.E., Weissman M.M., Orvaschel H., Gruenberg E., Burke J.D., et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry. 1984; 41(10): 949-58. https://doi.org/10.1001/archpsyc.1984.01790210031005

16. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003; 28(Suppl. 2): 17-54. DOI: https://doi.org/10.1016/s0306-4530(02)00125-7

17. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000; 401: 3-38. https://doi.org/10.1111/j.0065-1591.2000.0ap25.x

18. Seeman M.V., Lang M. The role of estrogen in schizophrenia gender differences. Schizophr. Bull. 1990; 16(2): 185-94. https://doi.org/10.1093/schbul/16.2.185

19. Bendas T.V. Gender Psychology [Gendernaya psikhologiya]. St. Petersburg: Piter; 2006. (in Russian)

20. Kohen D. Psychiatric services for women. Br. J. Psychiatry. 2001; 178: 296-8.

21. Goldstein J.M. Gender differences in the course of schizophrenia. Am. J. Psychiatry. 1988; 145(6): 684-9. https://doi.org/10.1176/ajp.145.6.684

22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington: American Psychiatric Association; 1994.

23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Arlington: American Psychiatric Association; 2013.

24. Regier D.A., Kuhl E.A., Kupfer D.J. The DSM-5: Classification and criteria changes. World psychiatry. 2013; 12(2): 92-8. https://doi.org/10.1002/wps.20050

25. WHO. International Classification of Diseases 11th Revision (ICD-11). Available at: http://www.who.int/classifications/icd/en/

26. Mosolov S.N. Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010; 110(6): 4-11. (in Russian)

27. Griesinger W. Die Pathologic und Therapie der psychischen Krankheiten. Braunsduweig: Verlag von Friedrich Wreden; 1871: 53-85. (in German)

28. Hoche A. Die Medizin der Gegenwart in Sellbstdarstellungen. Darmstadt; 1925. (in German)

29. Kotsyubinskiy A.P., Sheynina N.S., Burkovskiy G.V. Functional Diagnosis in Psychiatry [Funktsional’nyy diagnoz v psikhiatrii]. St. Petersburg: Spetslit; 2013. (in Russian)

30. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am. J. Psychiatry. 1997; 154(Suppl. 4): 1-63. https://doi.org/10.1176/ajp.154.4.1

31. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003; 60(6):553-64. https://doi.org/10.1001/archpsyc.60.6.553

32. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry. 2013; 14(1): 2-44. https://doi.org/10.3109/15622975.2012.739708

33. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Schizophrenia. 2nd edition. Am. J. Psychiatry. 2004; 161(Suppl. 2): 1-56.

34. Barnes T.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Psychopharmacol. 2011; 25(5): 567-620. https://doi.org/10.1177/0269881110391123

35. NICE Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178], March 2014. Available at: https://www.nice.org.uk/guidance/cg178

36. Register of medicines in Russia, 2016. Trevikta (Trevicta). Instructions for use, contraindications and composition. Available at: https://www.rlsnet.ru/ (in Russian)

37. Lyubov E.B. Paliperidone palmitate 3-month injection in schizophrenia: hope and experience. Sotsial’naya i klinicheskaya psikhiatriya. 2017; 27(1): 48-54. (in Russian)